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Introduction
Asthma is an obstructive airway disease characterized by inflamed airways, structural and physiological 
abnormalities of  the airways, and shortness of  breath (1). Although impressive progress has been made in 
the treatment of  asthma, there still is a significantly high number of  uncontrolled severe asthma (2) and 
asthma deaths worldwide, and consequently a great need for lifesaving therapy (3).
There are 11 isoenzyme families of  phosphodiesterases (PDEs). In the context of  allergic airway 
inflammation and asthma, PDE3 and PDE4 are most relevant and widely expressed in airway cells includ-
ing epithelial cells, endothelial cells, smooth muscle cells, and inflammatory cells (4–9). PDE3 has 2 iso-
forms (PDE3A and PDE3B) and is a cAMP- and cGMP-specific PDE; PDE4 has 4 isoforms (PDE4A, -B, 
-C, and -D) and is cAMP specific. PDE4 inhibitors appear to act effectively on immune cells, as well as on 
endothelial cells, epithelial cells, and airway smooth muscle cells (10). The lack or inhibition of  PDE4, an 
asthma susceptibility gene (11), attenuates airway hyperresponsiveness and airway inflammation in mouse 
models of  allergic airway inflammation (12–18). It is known that genetic variants of  PDE4D are associated 
with asthma (19) and PDE3 inhibition induces smooth muscle cell relaxation with the consequence of  
bronchodilation (20). Recently, research has focused on the synergy of  preparations that combine PDE3- 
and PDE4-inhibiting effects (21).
Increasing cAMP levels reduces the expression of  adhesion molecules and consequently impairs 
eosinophil and neutrophil adherence to human lung endothelial cells (6). PDE4 isoforms are expressed 
by both immune cells and structural tissue cells (22), but also in the brain (23), which makes broad-spec-
trum PDE4 inhibitors like roflumilast less promising as antiasthma drugs in humans (24). When PDE4 
inhibitors are dosed according to their advisory dose they may show frequently mild to severe side 
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effects including diarrhea, headache, and nausea. Even suicides have been reported (25). Presently, no 
specific PDE4 inhibitor is available for asthma.
Some promising results have been reported for the dual PDE3/4 inhibitor RPL554, which is 
already in a phase II clinical trial for asthma (21). Although RPL554 is described as a dual inhibitor, 
it is 3,750-fold more potent for PDE3 compared with PDE4. It has a half-life (t½) of  11 hours (21, 24) 
and was shown to be effective in an asthma model (7). PDE4 and combined PDE3/4 inhibition may 
enhance the effects of  glucocorticoid treatment (26, 27). Since the major action of  RPL554 is PDE3 
inhibition, it is important to know what the exact contribution of  PDE3 is to allergic airway inflamma-
tion. Several lines of  evidence support a critical role for PDE3 in cell-cell interactions, including endo-
thelial barrier function and cell junctions (28–31). The data available from PDE3 inhibitors during the 
1990s concerned only drugs with a short t½ and failed to show beneficial effects in asthma models, 
involving long incubation times. At the moment, RPL554 is the only drug available in experimental 
settings and has not been tested in patients with severe disease. We recently demonstrated beneficial 
and life-saving effects of  the PDE3 inhibitor enoximone in status asthmaticus (32), which were based 
on enoximone’s known bronchodilatory capacity (20). PDE3 inhibition literature of  the 1990s did not 
show any antiinflammatory effects in animal models of  allergic inflammation (33–36). We suggest 
that this absence of  proof  may be due to inadequate dosing, a wrong model, and limited use of  PDE3 
inhibitors. However, clinical data suggest that PDE3 inhibition therapy given via infusion in heart 
failure, bypass operations, and enterovirus 71 infection did show antiinflammatory effects (37–39). 
During the last decade, a growing number of  studies suggest that PDE3 inhibition might be involved 
in immunosuppression (40–48), although there is no definitive proof. There have been concerns that 
PDE3 inhibitors were associated with increased cardiovascular mortality in previous clinical trials (49, 
50). However, a better picture is given by the ESSENTIAL clinical trial (51), where the outcome of  
the study was that 150 mg oral enoximone per day compared with placebo neither improved advanced 
heart failure (HF) nor aggravated it, and did not show adverse effects even in heart failure patients.
Based on clinical observations, we wanted to investigate whether PDE3 inhibition might induce an 
antiallergic effect. We investigated the role of  PDE3 in an acute house dust mite–driven (HDM-driv-
en) allergic airway inflammation mouse model. We studied the phenotype of  PDE3A and PDE3B 
single-deficient mice. Moreover, we demonstrated the effect of  PDE3 inhibition in vivo. Both PDE3 
deficiency and pharmacological inhibition of  PDE3 activity reduced allergic airway inflammation and 
improved endothelial barrier function in this asthma model.
Results
High expression of  PDE3 and PDE4 in lung mucosal tissue obtained from healthy controls and asthmatic patients. 
To begin with, we studied protein and mRNA expression of  PDE3 and PDE4 isoforms in the airways and 
immune cells. PDE3A and PDE3B proteins were detected in the epithelium, endothelium, smooth muscle 
cells, and inflammatory cells. No differences in PDE3 protein (Supplemental Figure 1, A and B; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.94888DS1) or mRNA 
expression (Supplemental Figure 1C) were seen in human lung mucosal biopsies with eosinophilic airway 
inflammation (Supplemental Figure 1D) or murine lung mucosal samples using quantitative PCR (qPCR) 
(Supplemental Figure 2A). Cultured murine B cells and dendritic cells (DCs) expressed PDE3B (Supple-
mental Figure 2, B and C). IgM activation of  B cells induced increased expression of  PDE3B in B cells. 
HDM activation of  DCs reduced PDE3B expression. Naive and CD4+ T cells differentiated into various Th 
subsets, expressing high levels of  PDE3B, PDE4A, PDE4B, and PDE4D (Supplemental Figure 2D).
We found that although structural lung cells expressed both PDE3A and PDE3B, inflammatory cells 
expressed mainly the PDE3B isoform and PDE4.
Absence of  PDE3A or PDE3B expression results in a reduced inflammatory response in an HDM-driven allergic 
airway inflammation model in mice. Since PDE3 is widely expressed in lung cells, including inflammatory 
cells, we examined the specific role of  PDE3 in allergic airway inflammation. We investigated eosinophilic 
airway inflammation in 3 subsets of  mice: PDE3A–/– mice, PDE3B–/– mice, and WT littermates. We used 
an HDM-driven model for allergic airway inflammation according to the schedule depicted in Figure 1A. 
HDM-treated WT mice demonstrated a clear eosinophilic airway inflammation (Figure 1B). The numbers 
of  eosinophils in bronchoalveolar lavage (BAL) fluid were significantly higher in HDM-treated WT mice 
when compared with PBS-treated control mice (Figure 1C). The eosinophil number was 6-fold higher in WT 
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mice when compared with PDE3A–/– mice and 5-fold higher when compared with the PDE3B–/– mice (Fig-
ure 1C). Other inflammatory cell counts, including T cells, neutrophils, macrophages, and DCs, followed 
roughly the same pattern (Figure 1C and Supplemental Figure 2). T cells showed an approximately 3-fold 
higher number in HDM-treated WT mice when compared with HDM-treated PDE3A–/– or PDE3B–/– mice.
Figure 1. PDE3–/– mice showed diminished allergic airway inflammation. (A) An experimental house dust mite (HDM) asthma model was designed using 
intratracheal sensitization (s) and challenge (c) of 10 μg HDM or PBS as control. Analyses (a) were performed 1 day after the last challenge. Days after 
sensitization are indicated at the top. (B) Frozen lung sections were obtained from WT, PDE3A–/–, and PDE3B–/– mice treated with PBS or HDM and immu-
nohistochemically stained with rat antibodies against Siglec F (red) to identify eosinophils. The nuclei stained blue by means of Gills hematoxylin. All 
images are centered on at least one bronchiole with an accompanying blood vessel, surrounded by parenchymal alveolar space. Strongly positive dark red 
cells with a donut- or lobe-shaped nucleus were identified as eosinophils, whereas the larger, fainter red cells with a membrane staining were identified 
as alveolar macrophages. Original magnification, ×100. Scale bars: 100 μm. (C) FACS analysis and quantification of bronchoalveolar lavage (BAL) cells 
(total cells, eosinophils, T cells, DCs, macrophages, and neutrophils) were plotted in indicated populations. Kruskal-Wallis test for multiple comparisons 
was used followed by Mann-Whitney U test. Data represent 2 separate experiments (n = 3 for all PBS groups, n = 7 for WT HDM, n = 5 for both PDE3A–/– 
and PDE3B–/– HDM groups) and are shown as the mean ± SEM. *P < 0.05, **P < 0.01.
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All findings supported the hypothesis that the absence of  either PDE3A or PDE3B activity attenuates 
eosinophilic airway inflammation in an HDM-driven allergic airway inflammation model in mice.
PDE3A–/– and PDE3B–/– mice show a reduced Th2 cytokine response and a decreased level of  the proinflam-
matory cytokine TNF-α. The presence of  eosinophils is indirect proof  that a Th2 lymphocyte response to 
HDM was induced. Because the cellular inflammatory reaction was strongly reduced in PDE3A–/– mice 
and PDE3B–/– mice, we investigated whether this reaction was mitigated due to an impaired Th2 response. 
Indeed, both proportions and cell numbers of  IL-5– and IL-13–positive CD4+ T cells in BAL were reduced 
in HDM-treated PDE3A–/– and PDE3B–/– mice when compared with HDM-treated WT mice (Figure 2, A 
and B). As we had been able to demonstrate that both generalized inflammation and Th2-cell cytokine pro-
duction were less in both types of  PDE3–/–mice, we also investigated the cytokines produced in the alveolar 
lumen by BAL fluid analysis. We found lower levels of  the proinflammatory cytokine TNF-α and the Th2 
cytokine IL-5 in PDE3A–/– and PDE3A–/– mice when compared with WT mice in our model (Figure 2C). 
We were not able to demonstrate different keratinocyte-derived protein chemokine (KC) (murine IL-8) 
levels in HDM-treated WT, PDE3A–/–, and PDE3B–/– mice, compared with PBS-treated mice. Cytokine 
production is an important feature in allergies, so we next investigated cytokine production in in vitro 
HDM-restimulated, lung draining mediastinal lymph node (MLN) cells by ELISA. In WT mice MLN cul-
tures, we observed a marked increase of  IL-4, IL-5, and IL-13 (Figure 2D), indicating HDM-specific reac-
tivity of  MLN cells, most probably CD4+ T cells (Figure 2A). In contrast, MLN cultures from PDE3A–/– 
and PDE3B–/– mice showed markedly reduced Th2 cytokine production. On the other hand, IFN-γ was 
induced in all MLN cultures from WT, PDE3A–/– and PDE3B–/– mice at similar levels.
We concluded that HDM-reactive T helper cells in mice lacking PDE3 produce less Th2 cytokine, 
while IFN-γ is unaffected. Moreover, the proinflammatory cytokine TNF-α, as measured in BAL fluid, is 
lower in PDE3–/– mice, illustrating less pronounced immune activation when compared with WT mice in 
allergic airway inflammation.
PDE3A–/– and PDE3B–/– mice show reduced albumin leakage in an HDM-driven allergic airway inflammation 
model. Endothelial cells are an important target of  TNF-α, since its proinflammatory effects lead to increased 
permeability across endothelial cells. The next step in this study was to demonstrate this endothelial perme-
ability by analysis of  the leakage of  large serum proteins like albumin (52, 53). When endothelial barrier 
function is impaired, more albumin will leak through the airway’s endothelium into the lung mucosal tissue 
(edema), which in turn is responsible for additional airway narrowing in asthmatics (54). The PDE3 inhib-
itor cilostazol has been shown to improve barrier function by reducing leakage of  albumin in vitro (55). 
We studied albumin leakage in both lung tissue and alveolar lumen by ELISA, which is reliable, instead of  
indirect Evans blue dye techniques (52, 53, 56). Initially, PBS-treated WT, PDE3A–/–, and PDE3B–/– mice 
had albumin levels that are within the normal range. This implies that barrier function is unaffected under 
noninflammatory conditions. When challenged with HDM, WT mice displayed an increase in albumin 
content, suggesting greater leakage, which was not observed in the PDE3A–/– or PDE3B–/– mice (Figure 3A).
During inflammation, the vasculature leaks proteins because of  the large interendothelial cell spaces; 
as stated above, this leakage causes edema, which in turn causes additional airway narrowing in asthmatics. 
To investigate this, lung tissue sections were stained and analyzed for their albumin content (for details see 
the Methods; for quantification see Figure 3, B and C and representative examples D–L). Albumin inten-
sity was centered primarily on the airway vasculature in PBS-treated mice. Additionally, some albumin 
staining was seen in bronchial mucus in HDM-treated mice, indicating that during inflammation tissue 
albumin progresses into the mucus as well. However, most of  the direct leakage from the larger blood 
vessels was observed in the perivascular region (especially clear in the images of  Figure 3, D–F). When 
comparing HDM-treated WT mice (Figure 3, G and J) with PDE3A–/– and PDE3B–/– mice (Figure 3, H, 
I, K, and L), the peribronchial region directly surrounding the bronchioles appeared less albumin-infused 
in the PDE3A–/–and PDE3B–/– HDM-treated mice. When looking more closely at the peribronchial region 
(selections highlighted in white in Figure 3, J–L) it becomes apparent that in WT mice (Figure 3J) the small 
vasculature surrounding the bronchioli (highlighted with white arrows) was much more intensely stained 
for albumin when compared with the PDE3A–/– and PDE3B–/–mice (Figure 3, K and L). Compared with 
WT mice, HDM-treated PDE3A–/– mice displayed a significantly reduced increase of  albumin content in 
both peribronchial and perivascular leakage, whereas HDM-treated PDE3B–/– mice only significantly dif-
fered from the WT HDM-treated animals in terms of  peribronchial leakage. No marked differences were 
observed between the groups of  PBS-treated mice, indicating that no albumin leakage occurred.
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Figure 2. PDE3–/– mice showed diminished Th2 
cytokine in HDM-restimulated MLN cell suspen-
sion and BAL fluids. (A) Intracellular cytokine 
expression profiles (proportion and numbers) of 
gated bronchoalveolar lavage (BAL) CD3+CD4+ T 
cells upon 4 hours of PMA/ionomycin stimula-
tion. (B) Quantification of flow cytometric analy-
ses of the indicated populations of BAL CD3+CD4+ 
T cells. (C) BAL fluids were assayed with ELISA 
for indicated cytokines. (D) Single-cell suspen-
sions of mediastinal lymph node (MLN) cells 
were restimulated with 1 μg/ml house dust mite 
(HDM) for 7 days and supernatants were assayed 
with ELISA for indicated cytokines. Kruskal-Wal-
lis test for multiple comparisons was used fol-
lowed by Mann-Whitney U test. Data represent 
2 separate experiments (n = 3 for all PBS groups, 
n = 7 for WT HDM, n = 5 for both PDE3A–/– and 
PDE3B–/– HDM groups) and are shown as the 
mean ± SEM. *P < 0.05, **P < 0.01.
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In summary, the findings in these tests demonstrate that PDE3–/– mice had less vascular albumin leakage, 
indicating an improved barrier function under inflammatory conditions when compared with WT mice.
PDE3 inhibition attenuates allergic airway inflammation. Because lack of PDE3 activity improved the cardinal 
pathophysiological manifestations of  asthma including airway inflammation and edema formation, we 
Figure 3. Less albumin extravasation 
in HDM-treated PDE3–/– mice compared 
with WT mice. (A) Albumin content in 
bronchoalveolar lavage (BAL) fluids of WT 
versus PDE3–/– mice was assayed with ELI-
SA. Ranking score results of the peribron-
chial (B) and perivascular (C) albumin 
leakage judged from the lung tissue 
sections of WT and PDE3–/– mice. Frozen 
tissue sections of WT and PDE3–/– mice 
were stained for albumin (brown-red) and 
counterstained with Gills hematoxylin 
(blue) at ×5 (D–I) and ×20 magnification 
(J–L). Albumin positivity can be seen 
throughout the entirety of the lung 
tissue, but is mainly sequestered inside 
the large blood vessels, perivascular as 
well as peribronchial. Mucus was also 
stained for albumin. PBS-treated mice 
(A–C) were indistinguishable from each 
other concerning albumin content. WT 
HDM-treated mice (G and J) showed albu-
min positivity surrounding the bronchi-
oles when compared with PDE3–/– mice (H, 
I, K, and L). Original magnification, ×100. 
Zooming in on (×400) the peribronchial 
region (highlighted with white rectangle), 
the smaller vasculature surrounding the 
bronchiole is albumin-positive in WT mice 
(J) (highlighted with white arrows) when 
compared with the PDE3–/– mice (K and L). 
Kruskal-Wallis test for multiple compar-
isons was used followed by Mann-Whit-
ney U test. Data represent 2 separate 
experiments (n = 3 for all PBS groups, n = 
7 for WT HDM, n = 5 for both PDE3A–/– and 
PDE3B–/– HDM groups) and are shown as 
the mean ± SEM. *P < 0.05.
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proceeded by targeting PDE3 in a therapeutic intervention using a PDE3 inhibitor. Successful off-label use of  
the PDE3 inhibitor enoximone was described in the context of status asthmaticus (32). Next to its PDE3 inhibi-
tory properties (IC50 = 5.9 μM), enoximone also exhibits some PDE4 inhibitory effect, more specifically a myo-
cardial PDE4A inhibitory effect (IC50 = 21.1 μM) (57, 58). Cardiomyocytes express mainly PDE4A1A (59). 
We used an HDM-driven mouse model for allergic airway inflammation according to the schedule depicted in 
Figure 4A, with enoximone or diluent given via the intratracheal route. A significant reduction of airway inflam-
mation was seen in mice treated with optimal doses of enoximone (Figure 4, B–D and Supplemental Figure 4).
From these experiments, we concluded that targeting PDE3 — particularly during allergen challenge 
— prevents HDM-driven airway inflammation. Similar results were seen when enoximone was given via 
the oral route (Supplemental Figure 3).
Treatment with a PDE3 inhibitor reduces eosinophilia during ongoing allergic inflammation. We next investigat-
ed if  PDE3 inhibition with enoximone is capable of  attenuating airway inflammation in already established 
allergic airway inflammation. Prospectively, we created 3 different groups of  WT mice (Figure 5A). One 
group consisted of  PBS/diluent controls only. Two other groups were sensitized with HDM, followed by 
5 additional HDM challenges on days 10–14 thereafter. Mice with allergic airway inflammation were then 
challenged again on 5 successive days (days 15–19) with HDM admixed (given simultaneously) with diluent 
Figure 4. Topical enoximone abrogated 
HDM-induced allergic airway inflammation. 
(A) Experimental house dust mite (HDM) asth-
ma design showing intratracheal sensitization 
(s) and challenge (c) of 10 μg HDM admixed with 
diluent or 25 μg enoximone or PBS admixed 
with diluent or 25 μg enoximone as controls. 
Analyses (a) were performed 1 day after the 
last challenge. Days after sensitization are 
indicated at the top. Quantification of flow 
cytometric analyses of the indicated popula-
tions of bronchoalveolar lavage (BAL) cells (B), 
T cells and dendritic cells (C), and mast cells 
and basophils (D). Mann-Whitney U test was 
used. Data represent 2 separate experiments 
(n = 4 for all PBS groups, n = 8 for HDM groups) 
and are shown as the mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001.
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or enoximone (Figure 5A). At day 20, the controls showed no signs of  allergic inflammation in the BAL. 
The diluent-treated HDM-exposed mice showed significantly increased levels of  eosinophils, macrophages, 
group 2 innate lymphoid cells (ILC2s), and T cells, indicating an allergic reaction (Figure 5B). The enox-
imone-treated HDM-exposed mice showed significant reductions in inflammatory cell numbers including 
eosinophils, macrophages, ILC2s, and T cells, indicating that enoximone treatment reduced airway inflam-
mation (Figure 5B). Induction of  neutrophils was limited, but their numbers also tended to be lower in 
enoximone-treated mice compared with diluent-treated mice. We also investigated the numbers of  Th2 cyto-
kine–producing T cells and observed a significant reduction in IL-13–positive CD4+ T cells and IL-5–positive 
CD4+ T cells tended to be lower, while IFN-γ– and IL-17–producing T cells remained the same (Figure 5C).
These data showed that the PDE3 inhibitor enoximone substantially reduces established Th2-driven 
allergic airway inflammation in an HDM-driven asthma mouse model.
Milrinone, a PDE3 inhibitor with a short t½, showed an antiinflammatory effect. To confirm our enoximone 
data, another clinically available PDE3 inhibitor, milrinone, was investigated. Milrinone is a 5-fold more 
potent PDE3 inhibitor than enoximone (IC50 1.2 and 5.9 μmol/l, respectively) (57). It has a shorter t½ 
Figure 5. Topical (intratracheal) 
treatment with 25 μg enoximone 
reduced allergic airway inflam-
mation in established asthma in 
an HDM asthma model. (A) Exper-
imental house dust mite (HDM) 
asthma model using intratracheal 
sensitization (s) of 1 μg HDM or 
PBS as control and intranasal 
challenge with 5 μg HDM followed 
by challenge and treatment (chall/
treat). Days after sensitization are 
indicated at the top. (B) Quantifi-
cation of flow cytometric analyses 
of bronchoalveolar lavage (BAL) 
cells of the indicated populations. 
(C) Quantification of cytokines 
of BAL CD4+ T cells from flow 
cytometric analyses were plotted 
for indicated populations of BAL 
cells. Kruskal-Wallis test for 
multiple comparisons was used, 
followed by Mann-Whitney U test. 
Data (n = 4–5 animals per group) 
are expressed as the mean ± SEM. 
*P < 0.05, **P < 0.01.
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than enoximone (<2 hours vs. 7 hours, respectively). We performed a dose-response and timing variation 
study (Figure 6A) and observed that treatment with 10 μg milrinone intratracheally (i.t.) is as potent as 
25 μg enoximone i.t. in reducing eosinophilic airway inflammation when given during challenge (Figure 
6B). In addition, one group received 1 μg milrinone 2 hours before sacrificing (Figure 6A). In this group, a 
reduction was observed in eosinophilic airway inflammation (Figure 6B).
From these experiments, we concluded that targeting PDE3 with optimal doses and timing, milrinone 
also prevents HDM-driven allergic airway inflammation.
PDE3 inhibition and the expression of  CD11b. Given the fast antiallergic response, we investigated whether 
PDE3 effects on integrin might be associated in allergic airway inflammation. Mouse and human eosinophils 
express CD11b, an integrin that is crucial for immune cell extravasation (60). Elevated levels of CD11b in 
neutrophils and eosinophils were seen in affected lung tissue when compared with blood levels (61). Segmental 
lung antigen challenge upregulates and activates eosinophil integrins in blood and airways of asthmatics (62). 
From studies in the 1990s it is known that PDE4 inhibition and theophylline can rapidly reduce the expression 
of CD11b in neutrophils and eosinophils (63, 64). BAL eosinophils and neutrophils showed no differences 
in CD11b phenotype when they were obtained from mice lacking PDE3A or PDE3B or WT (Figure 7, A 
and B). BAL alveolar macrophages expressed lower levels of CD11b when they were obtained from PBS- or 
HDM-treated mice lacking PDE3A or PDE3B when compared with PBS- or HDM-treated WT mice (Figure 
7C). In vitro, 10 μM enoximone–treated BAL eosinophils induced by IL-33 treatment (65) showed significantly 
lower CD11b expression when compared with diluent-treated BAL eosinophils (Figure 7D).
Peripheral blood mononuclear cells (PBMCs) obtained from buffy coats were pretreated with either 
diluent or enoximone and activated with platelet activation factor (PAF), N-formylmethionyl-leucyl-phe-
nylalanine (fMLP), or diluent. PAF and fMLP induced the expression of  CD11b in eosinophils (Figure 
7E). Lower CD11b expression was observed in ex vivo samples pretreated with enoximone and stimulated 
with PAF or fMLP (Figure 7, F and G) when compared with diluent (n = 6). CD11b mean fluorescence 
Figure 6. PDE3 inhibitor half-life is 
important for its antiinflammatory 
effect. (A) Mice were sensitized (s) with 
house dust mite (HDM) on day 0 and 
then treated intratracheally with 0.01, 
0.1, 1, and 10 μg milrinone (milr) or 25 μg 
enoximone (enox) admixed with house 
dust mite (HDM). Analyses (a) were 
performed 1 day after the last challenge 
(c). The experiment was set up in such 
a way that the mice that received 1 μg 
milrinone were divided into 2 groups: 
one that received milrinone on a regular 
basis, every day, and the last dose 24 
hours before the mice were killed; and 
one that received the last dose of 1 μg 
milrinone 2 hours before the mice were 
killed. Days after sensitization are indi-
cated at the top. (B) Quantification of 
flow cytometric analyses of bronchoal-
veolar lavage (BAL) cells. Kruskal-Wallis 
test for multiple comparisons was used, 
followed by Mann-Whitney U test. Data 
represent 2 separate experiments (n = 
4–5 animals per group) and are shown as 
the mean ± SEM. *P < 0.05, **P < 0.01.
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intensity (MFI) reduction due to enoximone compared with diluent control treatment was seen in unstimu-
lated, fMLP-, or PAF-stimulated samples (summarized in Figure 7H). These findings imply that decreasing 
CD11b expression is one of  the antiinflammatory targeting mechanisms of  enoximone with similar char-
acteristics to PDE4 inhibitors.
Discussion
In our study, we provide evidence that PDE3 plays a pathophysiological role in allergic airway inflammation. 
In particular, we demonstrated in a physiologically relevant model that HDM-driven allergic inflamma-
tion is reduced by targeting PDE3, employing PDE3A- or PDE3B-knockout mice, or by pharmacological 
inhibition. This reduction was observed when pharmacological intervention was given orally, or topically 
by means of  admixing enoximone with HDM solution followed by intratracheal administration. Hereby, 
enoximone was also effective when administered to mice with established disease. This potentially novel 
antiinflammatory observation indicates that besides targeting PDE4 to reduce allergic airway inflammation 
(18, 66), targeting the related enzyme PDE3 also substantially reduces allergic airway inflammation.
The BAL fluid of  both PDE3A–/– and PDE3B–/– mice consequently contained significantly lower num-
bers of  inflammatory cells, including eosinophils, as well as less cytokines, when compared with the WT 
controls. T cell functionality was also affected, as demonstrated by a reduced ability of  HDM-restimulated 
MLN cells to produce and secrete inflammatory cytokines. An important aspect is that the endothelial 
Figure 7. PDE3 activity influences the CD11b expression in eosinophils, neutrophils, and alveolar macrophages. Bronchoalveolar lavage (BAL) cells 
expressing CD11b obtained from PBS-treated (n = 3) or house dust mite–treated (HDM-treated) (n = 6–8) PDE3A–/–, PDE3B–/–, or WT mice. (A) Eosinophils, (B) 
neutrophils, and (C) alveolar macrophages. (D) In vitro treatment of IL-33–induced BAL cells with the PDE3 inhibitor enoximone (10 μM) reduced the expression 
level mean fluorescence intensity (MFI) of CD11b on eosinophils in mice (n = 4). (E) Eosinophils stimulated with platelet activation factor (PAF) or N-formylme-
thionyl-leucyl-phenylalanine (fMLP) were activated and CD11b was induced. In vitro therapy with the PDE3 inhibitor enoximone reduced the expression level 
of CD11b induced by PAF (F) or fMLP (G). Summary graph compares MFIs from the samples and treatments described above (H). n = 6 different donors. Data 
represent 6 separate experiments and are shown as the mean ± SEM. *P < 0.05 by paired t test.
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barrier function, which is severely hampered in WT mice following treatment with HDM, was preserved in 
PDE3A–/– or PDE3B–/– mice. We observed the mechanisms, but the molecular delineation into the mode of  
action of  PDE3 isoforms in allergic airways disease remains to be clarified.
Inhibition of  PDE3 and elevation of  cAMP improved epithelial and endothelial barrier function and 
reduced smooth muscle cell proliferation, which represent important therapeutic effects in the context of  
asthma treatment (5). Both PDE3 and PDE4 play a key role in regulating cAMP-induced signalling. Levels 
of  intracellular cAMP are important for the type of  immune response and affect Th1 and Th2 responses, 
whereby increased levels of  cAMP were found to cause bronchodilation (67). Genome-wide studies in 
asthma identified an association with a PDE4D polymorphism that is linked to hyperactive PDE4. This 
polymorphism causes low intracellular levels of  cAMP in smooth muscle cells, which is associated with 
decreased forced exhaled volume in 1 second (FEV1) and bronchial hyperreactivity (11, 14, 68).
The side effects of  treatment with PDE4 inhibitors may be quite severe, physically as well as mental-
ly; even suicides have been reported (24, 69). PDE4 inhibitors are rarely prescribed nowadays, owing to 
these side effects. On the other hand, clinical observations indicate immediate bronchodilation in asthma 
patients (8, 36, 70) and in status asthmaticus patients when treated with the PDE3 inhibitor enoximone 
(32). We would like to underline that the dosage of  PDE3 inhibitor enoximone used in early studies that 
resulted in cardiovascular mortality was very high, 10- to 100-fold higher (up to 2,400 mg) than the dosage 
used in our case report study (ref. 32 and J. Beute unpublished data). Long-term use of  high-dose PDE3 
inhibitors is not suitable for heart failure patients (71). PDE3 inhibitor therapy is currently only used in 
heart failure patients to bridge the period to cardiac transplant and in the ICU to prevent organ failure.
This study shows that a low dose of  a not very potent (IC50 5.9 μM) PDE3 inhibitor is able to counteract 
allergic reactions, thereby avoiding severe consequences that may result from potent PDE4 inhibitors or high 
doses of  PDE3 inhibitor. Our model is suitable to study acute allergic inflammation. Studies are underway 
to investigate the role of  PDE3 in airway hyperresponsiveness in a chronic HDM-driven asthma model (A. 
KleinJan, manuscripts in preparation). The importance of  drug t½  is illustrated by the results of  the com-
parison between milrinone (t½ < 2 hours) and enoximone (t½ = 7 hours). The t½ is an important feature of  
effectiveness in allergic airway inflammation (Figure 6B), but at the same time it is not directly proportional 
to the effective duration of  the drug action. The difference might spring from the metabolite of  enoximone 
being bioactive versus the inactive metabolite of  milrinone (72). Earlier studies showed no antiallergic prop-
erties; however, the time in between drug administration moments was 24 hours and substantially longer 
than its t½, and the effect may have waned during incubation. Milrinone may be as effective as enoximone, 
showing an effect when given in a low dose 2 hours before sampling the mice, but it has to be kept in mind 
that the t½ of  milrinone in healthy subjects is probably less than 2 hours. This is a good feature for an intra-
venously administered drug (milrinone and enoximone presently are administered in an ICU setting in the 
treatment of  circulatory failure), but not for an oral drug that requires limited administration.
Our mouse data support the clinical observation of  the beneficial use of  enoximone in the treatment 
of  allergic asthma and show an antiinflammatory effect. The exact mechanism underlying the antiinflam-
matory effects of  enoximone have not yet been elucidated. PDE4 inhibition has a direct effect on the 
expression of  CD11b on eosinophils; this is also seen when applying enoximone. Evidence has shown 
that CD11b expression is also reduced by PDE3 mutants and by PDE3 inhibition as a stand-alone agent. 
When PBMCs were treated with enoximone, the cells could not be activated by PAF or fMLP. There is no 
difference in the expression level of  CD11b on eosinophils in either blood or in induced sputum between 
healthy controls and asthmatic patients. Although CD11b levels on eosinophils were higher in sputum than 
in blood, indicating that CD11b expression is location dependent and is the highest at the site of  inflam-
mation (61), analysis of  BAL eosinophils from enoximone- or diluent-treated HDM-challenged mice did 
not show any differences in CD11b expression, which is in line with human data from in ‘t Veen et al. (61). 
They also found the highest CD11b expression in the alveolar compartment, irrespective of  having asth-
ma or being healthy (61). A reduction in CD11b prevented extravasation of  the CD11b-expressing cells, 
keeping these cells in the circulation and preventing them from injuring the diseased organ. It has been 
established that eosinophils can be seen in the pulmonary lymph nodes in asthmatic mice (73). Therapeutic 
CD11b reduction enables the eosinophils to disappear via the lymphatic system or via cough and swallow 
and prevent extravasation from the circulation. The rapid reduction in CD11b expression in neutrophils 
and eosinophils due to PDE3 inhibition might be an explanation for why inflammatory cells rapidly disap-
pear when the airways were treated with the PDE3 inhibitors.
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The antiinflammatory effects of  enoximone have been established in other studies and are illustrated 
by reduced serum TNF-α levels during PDE3 inhibition, compared with dobutamine-treated septic patients 
(38). In alveolar epithelial cells, LPS-induced biosynthesis of  proinflammatory cytokines is regulated by 
cAMP and tightly controlled by PDEs, and can be reduced by PDE inhibitors (74). Reduction in eosino-
philic inflammation resulted in reduced exposure to peroxidase and peroxide and reactive oxygen species 
(75, 76). When endothelial cells were exposed to peroxide or other active oxides, permeability of  endothe-
lial cells increased, leading to leakage (77, 78).
We showed reduced endothelial albumin leakage, as measured by lower concentrations of  albumin in 
BAL fluid or tissue in mice lacking PDE3, or as measured in WT mice treated with a PDE3 inhibitor. We 
decided to measure the albumin content directly in BAL fluid and not via the indirect method of  Evans 
blue dye (52, 56). By measuring albumin in lavage or in tissue, we could clearly see a close correlation 
between inflammation and albumin concentration. Experimental lung edema and clinical lung edema can 
evidently be attenuated by selective PDE3 inhibition (44) and/or PDE4 inhibition (39, 44, 78–80).
Enoximone has the advantage that a low dose is already biologically active and has been in clinical use for 
more than 20 years. Theophylline relaxes human airway smooth muscle cells by inhibiting PDE3 (81). In this 
context it is of  note that theophylline has a nonselective PDE inhibitory activity and only a modest degree of  
bronchodilatory activity, including antiinflammatory and immunomodulatory activity (81). Using low doses 
of  clinically available PDE3 inhibitory drugs such as enoximone or milrinone, it is possible to bypass the seri-
ous side effects that were often seen when asthma patients were treated with the very potent PDE4 inhibitors.
In conclusion: (a) we demonstrated the presence of  PDE3 protein and mRNA in human and murine 
airway tissues, (b) we proved that PDE3 inhibition is an important therapeutic target in the context of  
allergic airway inflammation, and (c) we concluded that PDE3A or PDE3B deficiency or the inhibition of  
PDE3 may alleviate the symptoms of  allergic airway inflammation. PDE3 inhibitors including enoximone 
and milrinone are already on the market and in off-label use for other indications, such as pulmonary artery 
hypertension (PAH) in children (in the UK). Because our study strongly supports the conclusion that tar-
geting PDE3 in allergic airway inflammation may be a novel effective treatment strategy, further research 
is essential and desirable.
Methods
Patients for human bronchial biopsies. Patients that met the criteria for asthma, were nonsmoking mild asthma- 
tics, with an FEV1 greater than 60% predicted (or more than 1.5 liters because of safety aspects), greater than 
10% improvement of FEV1 after maximal bronchodilation and/or increased bronchial hyperresponsiveness 
(i.e., PC20 methacholine < 8 mg/ml), in a stable clinical condition, and sensitized for at least HDM (skin prick 
test) were enrolled in the study. Healthy controls showed no signs of sensitization and were not hyperreactive.
Animals. PDE3A–/– and PDE3B–/– C57BL/6 mice were previously described (82, 83) and showed no 
abnormalities regarding T cell development (data not shown). WT C57BL/6 mice were purchased from 
Envigo. Animals were kept under specific pathogen–free conditions, provided with water and food ad libi-
tum, and were used at the age of  6–12 weeks.
HDM allergic airway inflammation model. To induce airway inflammation, mice were anaesthetized with 
isofluorane and treated i.t. with 10 μg (or as indicated) HDM (Greer Laboratories) allergen extract in 50 
μl PBS on day 0 or using PBS only (84). Ten days later, anesthetized mice were challenged with 10 μg or 
0 μg HDM in 50 μl PBS intranasally (i.n.) for 5 consecutive days. Mice were sacrificed 24 hours after the 
last challenge and BAL was performed by flushing the lungs 3 times with 1 ml PBS containing ethylenedi-
aminetetraacetic acid (EDTA, Sigma-Aldrich) (Figure 2A).
Route of  treatment, oral and intratracheal doses. Measurements were performed 24 hours after the last challenge.
Optimal dose of  25 μg enoximone versus diluent (Figure 5) was administered with 5 μg HDM 
solution and used for intratracheal treatment, or diluent (10% ethanol + 40% glycerol + 50% Milli-Q 
water, pH 12)  was administered with 5 μg HDM solution. Controls were treated with 25 μg enoxim-
one administered with PBS or diluent administered with PBS. Mice underwent enoximone treatment 
only during challenge.
Treatment strategy 2: established HDM allergy model. C57BL/6 mice were sensitized with 10 μg HDM on 
day 0 and challenged with 5 μg HDM for 5 days on days 10–14. Subsequently, the mice were treated with 
5 μg HDM admixed with 25 μg enoximone or diluent for 5 days on days 15–19. The controls received only 
PBS (diluent). Twenty-four hours after the last challenge, all animals were sacrificed and sampled.
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Immunohistochemical staining. Stainings were performed in a half-automatic stainer (Sequenza). Ace-
tone-fixed slides were washed with PBS and incubated and blocked in diluted normal goat serum or normal 
rabbit serum (CLB). Sections were stained with mouse anti–human PDE3A (clone 2D7, Abnova), mouse 
anti–human PDE3B (clone F-9, Santa Cruz Biotechnology), or rabbit anti–human PDE4 (Fabgennix, cata-
log PD4-101AP). The primary antibody was detected using goat anti-mouse long-chain biotin-streptavidin 
conjugated to alkaline phosphatase (BioGenix), goat anti-rabbit conjugated to alkaline phosphatase (Sig-
ma-Aldrich), or goat anti-PE conjugated to alkaline phosphatase (Rockland, 600-105-387) and rabbit anti-
goat conjugated to alkaline phosphatase. After rinsing, slides were incubated with New Fuchsin substrate 
(Sigma-Aldrich). Some slides were stained with goat anti-albumin horseradish peroxidase (HRP) (Bethyl 
Laboratories, A90-134P) and incubated with Nova Red substrate (Vector). Finally, the sections were coun-
terstained with Gills triple-strength hematoxylin (Sigma-Aldrich) and mounted in VectaMount (Vector). 
Eosinophils were stained with antibodies against Siglec F (BD Biosciences, 552126) to identify eosinophilic 
airway inflammation.
Albumin quantification in lung mucosal sections. Albumin quantification was done by taking a representa-
tive image from each section and assigning it an ID. These images were then ranked in a blinded fashion 
(EPK and AKJ) from most to least stained in terms of  leakage either peribronchially or perivascularly. 
Once arranged, the IDs were used to relate which image belonged to which animal. This resulted in an 
arbitrary rank score to quantify the albumin leakage (Figure 3, K and L).
Analysis of  PDE expression. RNA was isolated from patient lung biopsies and mouse whole tissue using 
a Total RNA Purification Kit (Sigma-Aldrich). Purity of  the extracted RNA was verified using a Nano-
Drop 2000 Spectrophotometer (Thermo Fisher Scientific). From the RNA, cDNA was reverse transcribed 
using a RevertAid First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific). qPCR primers (for detailed 
description of  primer sequences see Supplemental Tables 1 and 2) specific for all PDE3 and -4 isoforms 
were designed, using a universal probe library (Roche Diagnostics), and checked for efficiency. Using SYBR 
Select Master Mix (Applied Biosystems), the cDNA was analyzed via qPCR, using a 7300 Real-Time PCR 
System (Applied Biosystems). Resulting data were normalized to relative expression of  household genes 
(β-actin in human and hypoxanthine-guanine phosphoribosyl transferase [HPRT] in mouse). Resulting 
data were further analyzed using the comparative Ct (2–ΔΔCt) method (85).
Flow cytometric analysis. BAL, lung cells, and MLN cells were collected for cellular differentiation 
by flow cytometry as previously described (84). Eosinophils were identified as cells within the granu-
locyte gate and positive for Siglec F. T cells were identified as cells in the lymphocyte gate and positive 
for CD3. DCs were identified as cells in the lymphocyte gate and positive for CD11c and MHCII. 
In some experiments, a fraction of  the isolated cells was stimulated with ionomycin (Sigma-Aldrich), 
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich), and GolgiPlug (BD Biosciences) at 37°C for 
4 hours. Then, cells were stained for CD3, CD4, and intracellularly for IL-4, IL-5, IL-13, IL-17, and 
IFN-γ, after fixation with 2% paraformaldehyde and permeabilization using a saponin-containing 
buffer. Fixable Aqua Live/Dead for 405 nm (Invitrogen, Molecular Probes) was used to distinguish 
between live and dead cells (84). Cells were analyzed using an LSRII flow cytometer (BD Biosciences) 
and FlowJo software (Tree Star Inc.). 
PDE inhibition of  eosinophils. PBMCs were isolated from buffy coats of  healthy blood donors (n = 6) by 
lysing the red blood cells with lysis buffer (NH4Cl) and washed with RPMI twice. Then, the cells were incu-
bated with enoximone, rolipram diluent, and PBS for 30 minutes at 37°C, and next stimulated with PAF 
(Sigma-Aldrich), fMLP (Sigma-Aldrich), or diluent for 1 hour and washed and stained with Siglec 8APC 
(Biolegend, 7C9) for eosinophils and markers for non-eosinophils, CD15PE-CF594 (BD Biosciences, W6D3), 
CD14EF450 (eBioscience, 61D3), and CD3AF700 (eBioscience, UCHT1). DAPI or Aqua Live/Dead was used 
to distinguish between live and dead cells. Based on forward scatter (FSC) and side scatter (SSC) to identify 
the granulocyte population, eosinophils were selected and CD11b (ICRF44) expression was evaluated on 
live eosinophils. Treatment of  cells was performed with 1 μM PAF and 10 μM fMLP and diluent (10% 
ethanol + 40% glycerol + 50% Milli-Q water), 25 μg/ml enoximone.
Statistics. Reported values are shown as the mean ± SEM. Statistical analyses were performed with 
SPSS (SPSS Inc.) using Kruskal–Wallis 1-way ANOVA followed by Mann-Whitney U test. Mann-Whitney 
U test was only performed if  the 1-way ANOVA test pointed to significance and the Sign t test for paired 
samples. Resulting P values less than 0.05 (*) and 0.01 (**) are indicated and considered significant. Tests 
that did not reach significance (P > 0.05) are not indicated.
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.94888
R E S E A R C H  A R T I C L E
Study approval. All participants provided informed written consent, which was approved by the medical 
ethics committee of  the Erasmus Medical Center, Rotterdam, The Netherlands. Data from these patients 
were previously described (86, 87); detailed descriptions of  the characterizations of  the bronchial mucosa 
biopsies obtained from asthmatics showed more eosinophils than those obtained from healthy controls 
— see Supplemental Figure 1E. Peripheral blood cells were isolated from buffy coats of  blood donors 
(Sanquin Bloedvoorziening, NVT nr. 0014.03, Rotterdam, The Netherlands). All animal experiments were 
approved by the Erasmus MC Animal Ethics Committee.
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